Nicotine Replacement Therapy Market is estimated to be US$ 302.6 billion by 2032 with a CAGR of 16.5% over the forecast period (2022-2032)

 


Nicotine Replacement Therapy help in reducing the withdrawal feelings by giving a small controlled amount of nicotine. Small amount of nicotine helps in satisfying craving for nicotine & reduces urge to smoke. NRT is given in the form of sprays, inhalers, gum, patches, lozenges, etc. but no harmful chemicals in tobacco. NRT works by releasing a lower and more slowly absorbed dose of nicotine which is compared to smoking. Nicotine nasal spray is available only by prescription. Nicotine nasal spray helps in delivering the nicotine to bloodstream rapidly because it is absorbed through nose. Nicotine nasal spray helps in relieving withdrawal of symptoms very quickly and to control nicotine cravings. FDA has recommended the spray to be prescribed for 3 month period and not to be used for longer than 6 months. Nicotine inhalers are available only by prescription. Nicotine inhalers are thin plastic tube with nicotine cartridge inside. Nicotine inhalers help in delivering most of the nicotine vapor to mouth and throat where it is absorbed into bloodstream. Nicotine inhalers dose is recommended between 4 and 20 cartridges a day by slowly tapering off over 6 months. Nicotine lozenges can be brought without prescription. Nicotine lozenges are available in two strength such as 2 mg and 4 mg. Nicotine is the main active ingredient in tobacco products which reinforces an individual to tobacco addiction behavior. Pharmacological effects of nicotine lead to tobacco addiction. Nicotine is the main alkaloid of tobacco smoke & has become the principal modulator of psychopharmacological effects associated with addiction. The evidence has determined that NRT can help to stop smoking and now well accepted. However, rising demand for nicotine replacement therapy has become the positive impact on target market growth.

The report “Nicotine Replacement Therapy Market, By Type (Inhalers, Lozenges, Gums, Patches, and Others), By Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy, and Others) and By Region (North America, Europe, Asia Pacific, Latin America, and Middle East & Africa) - Trends, Analysis and Forecast till 2032”

Key Highlights:

·         In July 2022, Dr. Reddy’s has launched the over-the-counter Nicotine Polacrilex Lozenges (a store brand version of Nicorette) in US market. These newly launched lozenges are available in 2mg & 4mg strength. Nicotine Polacrilex Lozenges will be used for cessation of smoking and will benefit consumers who want to quit smoking by reducing withdrawal symptoms such as nicotine cravings.

·         In June 2021, JB Chemicals has launched ‘NOSMOK’ new medicated Nicotine Lozenges. Newly launched ‘NOSMOK’ medicated nicotine lozenges will help in reducing urge to consume or smoke tobacco and help in relieving psychological & psychomotor withdrawal symptoms & thus, help them in tobacco cessation journey. Newly launched lozenges are available in mint flavor and in both sugar-based and sugar-free variants in 2mg and 4mg strength.

·         In May 2019, Nicorette has introduced new nicotne lozenges in bid to woo customers away from vaping. Nicorette brand is launching its first major product in 10 years, a coated ice mint lozenges. The ice coating will help in delivering a punch of minty flavor with smoother texture than other nicotine lozenges and also help in quitting smoking.

·         In January 2018, Cipla has launched ‘Nicotex Nicotine Patches’ which will help smoker to kick the habit in 12 weeks. Newly launched ‘Nicotex Nicotine Patch’ is a skin or transdermal patch which works on proven principle of nicotine replacement therapy and helps in quitting smoking in 12 weeks.

·         In November 2017, Glenmark Pharmaceuticals has launched new nicotine gum ‘Kwitz’. Newly launched nicotine gum is available in 2mg as an OTC product and 4mg as prescription product. Newly launched nicotine gum ‘Kwitz’ will help smokers to quit the smoking.

Analyst View:

Nicotine Replacement Therapy (NRT) has benefits like, nicotine gums & lozenges are generally sugar-free, nicotine nasal spray works faster when any one need it, nicotine patches are convenient and has to be put only once a day. Nicotine lozenges, gums, inhalers are substitutes and can be put in the mouth by an addicted individual and helps in controlling their dosages to help keep cravings under better control. Nicotine inhalers also works very quickly. Nicotine Replacement Therapy (NRT) helps in reducing the motivation to smoke cigarettes because the body gets nicotine from another safer method. However, essential benefits and rising demand for NRT is expected to boosts the demand for target market growth over the forecast period. As a result, market competition is intensifying, and both big international corporations and start-ups are vying to establish position in the market.

Before purchasing this report, request a sample or make an inquiry by clicking the following link:

https://www.prophecymarketinsights.com/market_insight/Insight/request-sample/5060

Key Market Insights from the report:

Nicotine Replacement Therapy Market accounted for US$ 60.0 billion in 2022 and is estimated to be US$ 302.6 billion by 2032 and is anticipated to register a CAGR of 16.5%. The Nicotine Replacement Therapy Market is segmented based on Type, Distribution Channel, and Region.

·         Based on Type, Nicotine Replacement Therapy Market is segmented into Inhalers, Lozenges, Gums, Patches, and others.

·         Based on Distribution Channel Nicotine Replacement Therapy Market is segmented into Hospital Pharmacy, Online Pharmacy, Retail Pharmacy, and others.

·         By Region, the Nicotine Replacement Therapy Market is segmented into North America, Europe, Asia Pacific, Latin America, Middle East & Africa.

Competitive Landscape & their strategies of Nicotine Replacement Therapy Market:

The prominent players operating in the Nicotine Replacement Therapy  Market includes, Cipla Limited, Johnson & Johnson Inc., GlaxoSmithKline plc., Pfizer Inc., Glenmark Pharmaceuticals Limited., Rubicon Research Pvt. Ltd., Lucy Goods Inc., Fertin Pharma Ltd., Japan Tobacco Inc., British American Tobacco plc., and others.

The market provides detailed information regarding the industrial base, productivity, strengths, manufacturers, and recent trends which will help companies enlarge the businesses and promote financial growth. Furthermore, the report exhibits dynamic factors including segments, sub-segments, regional marketplaces, competition, dominant key players, and market forecasts. In addition, the market includes recent collaborations, mergers, acquisitions, and partnerships along with regulatory frameworks across different regions impacting the market trajectory. Recent technological advances and innovations influencing the global market are included in the report.

About Prophecy Market Insights

Prophecy Market Insights is specialized market research, analytics, marketing/business strategy, and solutions that offers strategic and tactical support to clients for making well-informed business decisions and to identify and achieve high-value opportunities in the target business area. We also help our clients to address business challenges and provide the best possible solutions to overcome them and transform their business.

To know more

Contact Us:

Sales

Prophecy Market Insights

  1 860 531 2701

Email- sales@prophecymarketinsights.com

Website- www.prophecymarketinsights.com

 

Comments

Post a Comment

Popular posts from this blog

Humanized Liver Mice Model Market is estimated to be US$ 133.72 billion by 2030 with a CAGR of 5.30% during the forecast period

Image
Humanized Liver Mice Model Market   accounted for US$ 78.64 million in 2020 and is estimated to be US$ 133.72 million by 2030 and is anticipated to register a CAGR of 5.30%.  A lot of studies are underway to create novel humanized liver mouse models. Initially, liver mice models were created by implanting human liver cells or hepatic cancer cells into basic immune-deficient mice. The results, however, were inconsistent and unreliable. As a result, immune-deficient mice were developed, which spontaneously destroy the mice liver, allowing human liver cells to proliferate and replace it, resulting in stable humanized liver mice models. For example, a number of research projects are looking into using PPARalfa and AFC8-based mice models to develop humanized liver mice models. The report "Global Humanized Liver Mice Model Market, By Model (uPA-SCID, FRG KO Mice, TK-NOG Mice  and Other Models) By Application (Pharmacokinetics Studies, In-vivo Liver Toxicity Testing, Drug Metabolism Stud
Read more

Monkeypox Disease Diagnostics Market - The abrupt global expansion of the monkeypox virus has increased the demand for monkeypox diagnostics.

Image
  The virus that causes smallpox and the Monkeypox both belong to the same family of viruses. Two outbreaks of a disease resembling the pox in groups of monkeys used for study led to the discovery of monkeypox in 1958. However, it has been observed in various parts of the world except Africa, where it is primarily found. It results in symptoms that resemble the flu, such as fever, chills, and a rash that might take weeks to go away. Even though instances of monkeypox are uncommon, they are growing in Africa and other areas where they have never before occurred. The fact that monkeypox is a rare disease may lead a healthcare provider to first rule out other rash infections, such measles or chickenpox. A tissue sample from an open sore is the first step in the medical professional's diagnosis of monkeypox (lesion). After that, send to a lab for PCR (Polymerase Chain Reaction). Additionally, blood is drawn to test for antibodies or the monkeypox virus. Currently, there is no licens
Read more

Bipolar Disorder Market is estimated to be US$ 6.7 billion by 2030 with a CAGR of 2.3% during the forecast period

Image
Bipolar Disorder Market   accounted for US$ 5.3 billion in 2020 and is estimated to be US$ 6.7 billion by 2030 and is anticipated to register a CAGR of 2.3%. Bipolar disorder known as manic depression is a mental illness that brings low moods and severe high moods, thinking, changes in sleep and have periods in which they feel overly happy and energized and other side feel very sad, hopeless and sluggish. Bipolar disorder can cause severe disruption to a person’s life which can be treated with appropriate treatment and support. The report "   Global Bipolar Disorder Market, By Disorder (Bipolar I Disorder, Bipolar II Disorder, Cyclothymic Disorder), By Drug Class (Mood Stabilizer, Anticonvulsant, Antipsychotic Drugs, Antidepressant Drugs, and Antianxiety Drugs), By Mechanism of Action (Serotonin-Norepinephrine Reuptake Inhibitors, Selective Serotonin Reuptake Inhibitors, Monoamine Oxidase Inhibitors, Tricyclic Antidepressants, Beta Blockers, and Benzodiazepines), By Region (North
Read more